"In the last 100 years, numerous vaccines have become available for influenza prevention. In the United States, national vaccine policy recommends influenza vaccination annually for everyone older than age 6 months. There are multiple types of vaccine that use different inactivated, live-attenuated, and egg-free formulations. Recent efforts through WHO’s Global Action Plan for Influenza Vaccines and the Pandemic Influenza Preparedness framework supported efforts to increase vaccine manufacturing and laboratory capacity for identifying viruses for use in vaccines. The global pandemic influenza vaccine production capacity in 2015 was estimated to be 6.4 billion doses—a record level, but not enough to provide the potential need for 2 doses for even half the world’s population. The current timeline for vaccine production also limits the usefulness of pandemic vaccine, as reflected in 2009, when the bulk of pandemic vaccine was not available until after the peak of the pandemic. However, increased use of new vaccine formulations that do not rely on growing viruses in eggs, such as cell-based vaccine and recombinant protein vaccine, will reduce the time required for vaccine manufacturing. In addition, further expansion of seasonal influenza vaccine manufacturing capacity worldwide, and continued increases in use of vaccine, will facilitate pandemic vaccine production and global access to pandemic vaccines."